Developer docs
API playgroundTry for free, no card

Search company profiles

Xeltis

Full company profile

uuid0000ebn

Namestring
Xeltis
Legal namestring
Xeltis B.V.
Websiteurl
xeltis.com
Company typeenum
Private
Founded yearint
2006
Descriptiontext

Xeltis B.V. is a privately held, clinical-stage medical device company founded in 2006 and headquartered in Eindhoven, Netherlands, that develops restorative cardiovascular implants based on its proprietary Endogenous Tissue Restoration (ETR) platform. The ETR technology employs supramolecular polymers — a chemistry rooted in Nobel Prize-winning breakthroughs by Professor Jean-Marie Lehn — fabricated via electrospinning into microstructured implants that are gradually absorbed by the body and replaced by the patient's own living tissue. The company's lead product, aXess, is a restorative vascular access conduit for hemodialysis patients that demonstrated 100% secondary patency and 0% infection at 12 months in first-in-human trials and 79% secondary patency in the EU Pivotal Trial; it received CE Mark and FDA Breakthrough Device Designation. Two additional pipeline products — XABG (a small-diameter restorative coronary artery bypass graft) and Xplore 2 (a pediatric pulmonary heart valve) — extend the ETR platform to other cardiovascular indications.

Xeltis targets approximately 3 million hemodialysis patients globally per year and roughly 1 million CABG patients per year, addressing well-documented failure modes of existing solutions including thrombosis, stenosis, calcification, infection, and the surgical burden of saphenous vein harvesting. The business model is hardware sales of regulated implantable devices to hospitals and specialized dialysis centers via a direct enterprise field sales motion, supplemented by a Greater China licensing partnership with Grand Pharmaceutical Group. The company is pre-revenue with commercialization in Europe and the US anticipated in 2026.

Xeltis has raised over €150 million across multiple funding rounds from a syndicate including the European Investment Bank, European Innovation Council Fund, EQT Life Sciences, DaVita Venture Group, Invest-NL, VI Partners, Ysios Capital, Kurma Partners, and Grand Pharmaceutical Group. The leadership team is led by CEO Eliane Schutte (appointed 2018, two-time Top 50 Healthcare Technology CEO) and includes CTO Rob Eyers, CMO Paulo Neves, COO Luciën van Os, and CFO Alexander Goemans, supported by an advisory board anchored by Nobel Laureate Jean-Marie Lehn. The company operates clinical programs across 9 European countries and the US, with the FDA-approved US pivotal trial enrolling up to 140 patients alongside the completed EU pivotal trial of 120 patients.

Short descriptiontext

Xeltis is a clinical-stage medtech company developing restorative cardiovascular devices — including the aXess hemodialysis conduit, XABG coronary bypass graft, and Xplore 2 pulmonary valve — based on a proprietary supramolecular polymer platform that enables implants to be gradually replaced by patients' own living tissue.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersEindhoven, Netherlands
HQ citystring
Eindhoven
HQ countrystring
Netherlands
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
restorative cardiovascular devices, vascular access conduits, hemodialysis access grafts, coronary artery bypass grafts, bioabsorbable polymer implants
Industry3 codes
PRIMARYHLAHAFAK
Vascular Access & Closure Devices (Sheaths, Guidewires, Closure Systems)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAHAFAA
Coronary Stents & Drug-Eluting Technologies
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAHAFAL
Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
NAICS code3 codes
  • Surgical and Medical Instrument Manufacturing339112
  • Medical Equipment and Supplies Manufacturing3391
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
Product category
Cardiovascular Medical Devices
Social media profiles3 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Medical Device Sales (Pre-Revenue)
TypeHardware Sales
Description

Xeltis is a pre-revenue clinical-stage medtech company. Revenue will be generated through the sale of its implantable medical devices (aXess, XABG, pulmonary valves) to hospitals and healthcare providers upon regulatory approval. The company is preparing for commercialization with CE Mark recently obtained for aXess and US market approval anticipated in 2026.

news.europawire.eu
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1aXess
Description

Restorative vascular access conduit for hemodialysis patients that enables creation of new, permanent, living vessels for vascular access

xeltis.com
+3 more records
Core offering1 text field

Xeltis develops and manufactures implantable, bioabsorbable cardiovascular devices — primarily artificial vessels and heart valves — built on its proprietary Endogenous Tissue Restoration (ETR) platform using supramolecular polymers. Its lead product aXess is a restorative vascular access conduit for hemodialysis patients, and the company is also advancing XABG (coronary artery bypass graft) and Xplore 2 (pediatric pulmonary heart valve). The company is preparing for commercialization with CE Mark obtained for aXess and FDA Breakthrough Device Designation granted in the US.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 79% secondary patency at 12 months in EU pivotal trial, significantly higher than conventional AV grafts
+4 more records
Product overview1 text field

Xeltis is a medtech company developing transformative vascular implants based on its proprietary Endogenous Tissue Restoration (ETR) platform. The company offers a portfolio of restorative cardiovascular devices: aXess (vascular access conduit for hemodialysis), XABG (coronary artery bypass graft), and Xplore 2 (pulmonary heart valve). These implants are designed to be gradually replaced by the patient's own living tissue, reducing risks of thrombosis, stenosis, calcification, and infection associated with conventional vascular grafts and valves.

Product and service3 records
1aXess Vascular Access Conduit
CategoryCardiovascular medical device — hemodialysis vascular access
Description

Restorative arteriovenous vascular access conduit for hemodialysis patients who cannot receive an AV fistula; combines AV fistula safety and patency with AV graft speed to treatment, designed to become the patient's own living vessel via the ETR platform. Targeted at vascular surgeons, nephrologists, dialysis centers and hospitals in the EU and US (CE Mark obtained; FDA pivotal trial underway, up to 140 patients).

2XABG Coronary Artery Bypass Graft
CategoryCardiovascular medical device — coronary artery bypass graft
Description

Restorative synthetic small-diameter (4mm diameter, 15cm length) coronary artery bypass graft designed to turn into a living blood vessel when colonized by the patient's own tissue via the ETR platform; intended as an alternative to saphenous vein harvest in CABG surgery. Preclinical data showed unprecedented one-year patency in large-animal models. Targeted at cardiac surgeons and cardiac surgery centers.

3Xplore 2 Pulmonary Heart Valve Conduit
CategoryCardiovascular medical device — pediatric pulmonary heart valve
Description

Restorative pulmonary heart valve conduit for pediatric patients requiring pulmonary valve replacement, built on the ETR platform; designed to integrate with the patient's growing tissue and potentially reduce repeated replacement surgeries. Early outcomes from Xplore-1 and Xplore-2 trials demonstrate excellent safety and performance. Targeted at pediatric cardiac surgeons and congenital heart disease centers.

Scale indicator14 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Humacyte develops bioengineered human acellular vessels for vascular access (dialysis) and vascular trauma indications — the most direct peer to Xeltis' aXess program. Both companies are pursuing regenerative vascular graft approaches to displace ePTFE grafts in hemodialysis, and Xeltis' VP of US Clinical Affairs previously worked at Humacyte.

TypeDirect peer
Description

Gore is the dominant incumbent in synthetic vascular grafts (GORE-TEX) used for hemodialysis vascular access and peripheral vascular reconstruction. Xeltis' aXess is explicitly positioned to displace this standard of care. Gore also acquired InnAVasc Medical in 2022, where Xeltis' current US VP of Clinical Affairs previously served.

3LeMaitre Vascular
TypeDirect peer
Description

LeMaitre Vascular specializes in vascular grafts, patches, and carotid shunts used in vascular surgery — directly overlapping with Xeltis' vascular access and reconstructive vascular indications across EU and US hospitals.

TypeDirect peer
Description

Artivion (formerly CryoLife) is a leader in preserved human tissues and mechanical heart valves for cardiac and vascular surgery, making it a direct peer to Xeltis' Xplore 2 pulmonary valve and broader cardiac surgery applications.

TypeBroad incumbent
Description

Edwards is a global leader in heart valve replacement and hemodynamic monitoring, with established transcatheter and surgical valve franchises. It is a broad incumbent in cardiac surgery — the same clinical specialty where Xeltis' Xplore 2 and future valve indications will compete.

TypeBroad incumbent
Description

Medtronic operates across the cardiovascular device spectrum — including CABG and heart valve products — and is the broader incumbent against which Xeltis' XABG and valve programs will compete. Xeltis' COO previously led international cardiovascular development at Medtronic.

7Abbott
TypeBroad incumbent
Description

Abbott manufactures cardiovascular devices including surgical valve and coronary intervention products. Xeltis' CMO has prior consulting experience with Abbott, and Abbott represents a broad incumbent in the CABG and heart valve categories Xeltis targets.

TypeBroad incumbent
Description

Boston Scientific is a major cardiovascular device incumbent with peripheral vascular and structural heart franchises. Xeltis' CTO Rob Eyers previously served as R&D Director at Boston Scientific, and the company's broad portfolio competes with Xeltis' peripheral and cardiac indications.

TypeEmerging player
Description

CorMatrix develops bioengineered ECM-based materials for cardiac and vascular repair, representing an emerging adjacent peer in regenerative cardiovascular implants. It pursues overlapping indications (pericardial repair, vascular reconstruction) with Xeltis' ETR platform.

TypeBroad incumbent
Description

BD is a broad incumbent in vascular access and dialysis-related medical devices, supplying catheters and access products to the same nephrology and vascular surgery channels where Xeltis intends to commercialize aXess.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds12 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors11 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Xeltis

Cardiovascular Medical Devicesxeltis.com

Xeltis is a clinical-stage medtech company developing restorative cardiovascular devices — including the aXess hemodialysis conduit, XABG coronary bypass graft, and Xplore 2 pulmonary valve — based on a proprietary supramolecular polymer platform that enables implants to be gradually replaced by patients' own living tissue.

What Xeltis does

Xeltis B.V. is a privately held, clinical-stage medical device company founded in 2006 and headquartered in Eindhoven, Netherlands, that develops restorative cardiovascular implants based on its proprietary Endogenous Tissue Restoration (ETR) platform. The ETR technology employs supramolecular polymers — a chemistry rooted in Nobel Prize-winning breakthroughs by Professor Jean-Marie Lehn — fabricated via electrospinning into microstructured implants that are gradually absorbed by the body and replaced by the patient's own living tissue. The company's lead product, aXess, is a restorative vascular access conduit for hemodialysis patients that demonstrated 100% secondary patency and 0% infection at 12 months in first-in-human trials and 79% secondary patency in the EU Pivotal Trial; it received CE Mark and FDA Breakthrough Device Designation. Two additional pipeline products — XABG (a small-diameter restorative coronary artery bypass graft) and Xplore 2 (a pediatric pulmonary heart valve) — extend the ETR platform to other cardiovascular indications.

Xeltis targets approximately 3 million hemodialysis patients globally per year and roughly 1 million CABG patients per year, addressing well-documented failure modes of existing solutions including thrombosis, stenosis, calcification, infection, and the surgical burden of saphenous vein harvesting. The business model is hardware sales of regulated implantable devices to hospitals and specialized dialysis centers via a direct enterprise field sales motion, supplemented by a Greater China licensing partnership with Grand Pharmaceutical Group. The company is pre-revenue with commercialization in Europe and the US anticipated in 2026.

Xeltis has raised over €150 million across multiple funding rounds from a syndicate including the European Investment Bank, European Innovation Council Fund, EQT Life Sciences, DaVita Venture Group, Invest-NL, VI Partners, Ysios Capital, Kurma Partners, and Grand Pharmaceutical Group. The leadership team is led by CEO Eliane Schutte (appointed 2018, two-time Top 50 Healthcare Technology CEO) and includes CTO Rob Eyers, CMO Paulo Neves, COO Luciën van Os, and CFO Alexander Goemans, supported by an advisory board anchored by Nobel Laureate Jean-Marie Lehn. The company operates clinical programs across 9 European countries and the US, with the FDA-approved US pivotal trial enrolling up to 140 patients alongside the completed EU pivotal trial of 120 patients.

Xeltis firmographics

Firmographics
Name
Xeltis
Legal name
Xeltis B.V.
Website
https://xeltis.com
Company type
Private
Founded year
2006
Operating status
Operating
Headcount range
51–100 employees
Short description
Xeltis is a clinical-stage medtech company developing restorative cardiovascular devices — including the aXess hemodialysis conduit, XABG coronary bypass graft, and Xplore 2 pulmonary valve — based on a proprietary supramolecular polymer platform that enables implants to be gradually replaced by patients' own living tissue.
Ownership category
akta.pro rank

Xeltis industry classification

Industry
Product category
Cardiovascular Medical Devices
NAICS
Surgical and Medical Instrument Manufacturing (339112), Medical Equipment and Supplies Manufacturing (3391), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
akta.pro industry
PRIMARYHLAHAFAK
Vascular Access & Closure Devices (Sheaths, Guidewires, Closure Systems)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAHAFAA
Coronary Stents & Drug-Eluting Technologies
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAHAFAL
Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)

Keywords

  • Restorative cardiovascular devices
  • Vascular access conduits
  • Hemodialysis access grafts
  • Coronary artery bypass grafts
  • Bioabsorbable polymer implants

Where Xeltis is headquartered

Location

Headquarters

HQ city
Eindhoven
HQ country
Netherlands
HQ region
Europe

Offices2 records

Markets served

Xeltis business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

  1. Medical Device Sales (Pre-Revenue): Xeltis is a pre-revenue clinical-stage medtech company. Revenue will be generated through the sale of its implantable medical devices (aXess, XABG, pulmonary valves) to hospitals and healthcare providers upon regulatory approval. The company is preparing for commercialization with CE Mark recently obtained for aXess and US market approval anticipated in 2026.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Xeltis product offering

Product offering

Core offering

Xeltis develops and manufactures implantable, bioabsorbable cardiovascular devices — primarily artificial vessels and heart valves — built on its proprietary Endogenous Tissue Restoration (ETR) platform using supramolecular polymers. Its lead product aXess is a restorative vascular access conduit for hemodialysis patients, and the company is also advancing XABG (coronary artery bypass graft) and Xplore 2 (pediatric pulmonary heart valve). The company is preparing for commercialization with CE Mark obtained for aXess and FDA Breakthrough Device Designation granted in the US.

Product overview

Xeltis is a medtech company developing transformative vascular implants based on its proprietary Endogenous Tissue Restoration (ETR) platform. The company offers a portfolio of restorative cardiovascular devices: aXess (vascular access conduit for hemodialysis), XABG (coronary artery bypass graft), and Xplore 2 (pulmonary heart valve). These implants are designed to be gradually replaced by the patient's own living tissue, reducing risks of thrombosis, stenosis, calcification, and infection associated with conventional vascular grafts and valves.

Differentiator

Problem solved

Functional benefit

Brands

  • aXess: Restorative vascular access conduit for hemodialysis patients that enables creation of new, permanent, living vessels for vascular access
  • XABG
  • Xplore 2
  • RestoreX

Products and services

  • aXess Vascular Access Conduit Restorative arteriovenous vascular access conduit for hemodialysis patients who cannot receive an AV fistula; combines AV fistula safety and patency with AV graft speed to treatment, designed to become the patient's own living vessel via the ETR platform. Targeted at vascular surgeons, nephrologists, dialysis centers and hospitals in the EU and US (CE Mark obtained; FDA pivotal trial underway, up to 140 patients).
  • XABG Coronary Artery Bypass Graft Restorative synthetic small-diameter (4mm diameter, 15cm length) coronary artery bypass graft designed to turn into a living blood vessel when colonized by the patient's own tissue via the ETR platform; intended as an alternative to saphenous vein harvest in CABG surgery. Preclinical data showed unprecedented one-year patency in large-animal models. Targeted at cardiac surgeons and cardiac surgery centers.
  • Xplore 2 Pulmonary Heart Valve Conduit Restorative pulmonary heart valve conduit for pediatric patients requiring pulmonary valve replacement, built on the ETR platform; designed to integrate with the patient's growing tissue and potentially reduce repeated replacement surgeries. Early outcomes from Xplore-1 and Xplore-2 trials demonstrate excellent safety and performance. Targeted at pediatric cardiac surgeons and congenital heart disease centers.

Quantifiable outcome

  • 79% secondary patency at 12 months in EU pivotal trial, significantly higher than conventional AV grafts
  • +4 more outcomes

Companies that use Xeltis

Customer profile

Named customers6 records

Segments3 records

Ideal customer profiles3 records

Xeltis technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Xeltis partnerships and signals

Strategic signal

Scale indicators14 records

Recent moves6 records

Expansion highlights6 records

Xeltis competitors and assessment

Company assessment

Direct peers

  • Humacyte: Humacyte develops bioengineered human acellular vessels for vascular access (dialysis) and vascular trauma indications — the most direct peer to Xeltis' aXess program. Both companies are pursuing regenerative vascular graft approaches to displace ePTFE grafts in hemodialysis, and Xeltis' VP of US Clinical Affairs previously worked at Humacyte.
  • W. L. Gore & Associates: Gore is the dominant incumbent in synthetic vascular grafts (GORE-TEX) used for hemodialysis vascular access and peripheral vascular reconstruction. Xeltis' aXess is explicitly positioned to displace this standard of care. Gore also acquired InnAVasc Medical in 2022, where Xeltis' current US VP of Clinical Affairs previously served.
  • LeMaitre Vascular: LeMaitre Vascular specializes in vascular grafts, patches, and carotid shunts used in vascular surgery — directly overlapping with Xeltis' vascular access and reconstructive vascular indications across EU and US hospitals.
  • Artivion: Artivion (formerly CryoLife) is a leader in preserved human tissues and mechanical heart valves for cardiac and vascular surgery, making it a direct peer to Xeltis' Xplore 2 pulmonary valve and broader cardiac surgery applications.

Broad incumbents

  • Edwards Lifesciences: Edwards is a global leader in heart valve replacement and hemodynamic monitoring, with established transcatheter and surgical valve franchises. It is a broad incumbent in cardiac surgery — the same clinical specialty where Xeltis' Xplore 2 and future valve indications will compete.
  • Medtronic: Medtronic operates across the cardiovascular device spectrum — including CABG and heart valve products — and is the broader incumbent against which Xeltis' XABG and valve programs will compete. Xeltis' COO previously led international cardiovascular development at Medtronic.
  • Abbott: Abbott manufactures cardiovascular devices including surgical valve and coronary intervention products. Xeltis' CMO has prior consulting experience with Abbott, and Abbott represents a broad incumbent in the CABG and heart valve categories Xeltis targets.
  • Boston Scientific: Boston Scientific is a major cardiovascular device incumbent with peripheral vascular and structural heart franchises. Xeltis' CTO Rob Eyers previously served as R&D Director at Boston Scientific, and the company's broad portfolio competes with Xeltis' peripheral and cardiac indications.
  • BD (Becton Dickinson): BD is a broad incumbent in vascular access and dialysis-related medical devices, supplying catheters and access products to the same nephrology and vascular surgery channels where Xeltis intends to commercialize aXess.

Emerging players

  • CorMatrix Cardiovascular: CorMatrix develops bioengineered ECM-based materials for cardiac and vascular repair, representing an emerging adjacent peer in regenerative cardiovascular implants. It pursues overlapping indications (pericardial repair, vascular reconstruction) with Xeltis' ETR platform.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Xeltis social profiles

Digital presence

Xeltis financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Xeltis leadership team

Management profile

Number of profiles

Profiles12 records

Xeltis funding detail

Funding detail

Funding overview

Funding rounds12 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Xeltis M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Xeltis

What does Xeltis do?

Xeltis develops and manufactures implantable, bioabsorbable cardiovascular devices — primarily artificial vessels and heart valves — built on its proprietary Endogenous Tissue Restoration (ETR) platform using supramolecular polymers. Its lead product aXess is a restorative vascular access conduit for hemodialysis patients, and the company is also advancing XABG (coronary artery bypass graft) and Xplore 2 (pediatric pulmonary heart valve). The company is preparing for commercialization with CE Mark obtained for aXess and FDA Breakthrough Device Designation granted in the US.

Is Xeltis a public or private company?

Xeltis is a private company. It is classified as venture growth investor backed and is currently operating.

When was Xeltis founded?

Xeltis was founded in 2006. It employs 51 to 100 people.

Where is Xeltis based?

Xeltis is headquartered in Eindhoven, Netherlands, in the Europe region.

How does Xeltis make money?

One revenue line is on record: medical Device Sales (Pre-Revenue).

Who are Xeltis's main competitors?

Direct peers on record are Humacyte, W. L. Gore & Associates, LeMaitre Vascular and Artivion. Broad incumbents are Edwards Lifesciences, Medtronic, Abbott, Boston Scientific and BD (Becton Dickinson). CorMatrix Cardiovascular is listed as an emerging player.

Does Xeltis have an API?

No public API is recorded for Xeltis.

What industry is Xeltis in?

Xeltis's product category is Cardiovascular Medical Devices. Its primary akta.pro industry code is HLAHAFAK, Vascular Access & Closure Devices (Sheaths, Guidewires, Closure Systems), with a secondary code of HLAHAFAA, Coronary Stents & Drug-Eluting Technologies. Its NAICS code is 339112 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Nelson Advisors BlogThis Week in European HealthTech, MedTech and Health AI: 7th August 2026The European HealthTech sector saw significant capital inflows in early August 2026, with companies like Xeltis and Qureight securing funding for clinical-grade medtech and AI diagnostics. Concurrently, the EU AI Act entered enforcement on August 2nd, though compliance timelines for medical devices were deferred to ease manufacturer burdens. In the UK, NHS England accelerated its £10 billion technology investment to roll out ambient voice technology and AI triage tools across healthcare trusts.Med-Tech InsightsXeltis raises an additional €20.5m of funding to advance aXess toward FDA approval and US commercial launchXeltis raised an additional €20.5m in funding led by new investor Horizon 3 Healthcare to advance its aXess product toward FDA approval and US commercial launch. The capital will support the finalization of the US pivotal trial, European commercial rollout, manufacturing upscaling, and further clinical development of XABG and XPAD programs.StartupmafiaDutch-US MedTech Xeltis Raises €20.5M to Advance Regenerative Blood Vessel TechnologyXeltis raised €20.5 million in new funding led by Horizon 3 Healthcare to advance its regenerative vascular implants. The financing will support a pivotal U.S. clinical trial for aXess™, which has enrolled over half of its target participants, and prepare for an FDA submission. The company also plans to expand European commercialization and develop additional regenerative cardiovascular products.Tech.euEuropean tech weekly recap: €878M in weekly deals and key trends from H1 2026Last week, over 50 European tech funding deals worth more than €878 million were tracked, plus over 10 exits and M&A transactions. In H1 2026, European tech companies raised €44.1 billion across 1,740 deals, with the UK leading at €18.7 billion and AI startups securing €5.92 billion.Medical BuyerXeltis raises €20.5M in new fundingXeltis announced it raised €20.5 million in new funding led by new investor Horizon 3 Healthcare, with participation from existing shareholders including the European Innovation Council, Invest-NL, VI Partners, EQT Life Sciences, and DaVita. The proceeds will support the completion of the US pivotal trial of aXess, prepare for FDA submission and US market launch, advance European commercialization, scale manufacturing, and progress the XABG and XPAD clinical programs. The fundraising follows the recent European launch of aXess with the first commercial patient treated in Germany and underscores continued investor confidence in the company's vascular access technology.BioWorldFinancings for July 29, 2026On July 29, 2026, biopharma and med-tech companies including Aurenar, Claris, Core, Coremap, Dopl, Enlivex, Medtronic, Sanofi, Scribe, Torrey, and Xeltis raised money in public or private financings. The list covers both public and private financing activities.EU-StartupsDutch-US MedTech Xeltis raises €20.5 million to advance artificial vessels and valves replaced by patients’ own tissueXeltis, a Dutch-US MedTech company developing artificial vessels and valves that are gradually replaced by patients' own living tissue, has raised €20.5 million in new funding from investors including Horizon 3 Healthcare, European Innovation Council, Invest-NL, VI Partners, EQT Life Sciences, and DaVita. The funding will support the completion of the US pivotal trial for aXess™, preparation for FDA submission, European commercial rollout, and advancement of XABG and XPAD clinical programs. The company's aXess™ product, which received CE Mark approval, has already treated its first commercial patient in Germany.Medical Device NetworkXeltis sharpens US market roadmap after €20.5m fundraiseXeltis, a Netherlands-headquartered vascular graft specialist, has raised €20.5m ($23.3m) in financing led by new investor Horizon 3 Healthcare, with participation from existing investors including the European Innovation Council, Invest-NL, and EQT Life Sciences. The funds will support US market preparation for the company's aXess bioabsorbable haemodialysis graft, which secured European CE mark approval in April 2026, and advance the ongoing pivotal trial that has enrolled over 50% of its planned 140 patients.MassDeviceXeltis raises $23.3M to bring vascular access device to USXeltis, an Eindhoven-based medical device company, has raised $23.3 million (€20.5m) in funding from new and existing shareholders, including Horizon 3 Healthcare, European Innovation Council, Invest-NL, VI Partners, EQT Life Sciences, and DaVita. Combined with $55 million raised at the end of 2025, the funding will support the company's U.S. pivotal trial for its aXess restorative vascular access conduit, FDA submission, U.S. market launch, European rollout, and manufacturing scale-up. The company began commercial activity for aXess earlier this month.GlobeNewswireXeltis raises an additional €20.5m of funding to advance aXess™ toward FDA approval and US commercial launchXeltis announced it raised an additional €20.5m in funding, led by new investor Horizon 3 Healthcare and joined by existing investors including the European Innovation Council, Invest-NL, VI Partners, EQT Life Sciences, and DaVita. The funding brings total capital raised in 2025-2026 to €70.5m combined with the €50m secured earlier from the European Investment Bank. Proceeds will support completion of the US pivotal trial for aXess™ (now exceeding 50% enrollment), FDA submission and US market preparation, European commercial rollout following the first commercial patient treated in Germany, manufacturing scale-up, and advancement of XABG and XPAD clinical programs.